Progenika starts EU marketing of diagnostic chip
Bilbao – Spanish Progenika Biopharma S.A has gained the green light for sale of its LPLchip in Europe. The DNA chip, which has achieved the CE mark, detects approximately 120 mutations in the lipoprotein lipase (LPL) gene and can be used to diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD), according to the company. The test has been developed under an agreement with Amsterdam Molecular Therapeutics Holding N.V. (Euronext: AMT), which has a gene therapy for patients with LPLD. AMT expects a regulatory decision on its MAA for its gene therapy product Glybera for lipoprotein lipase deficiency (LPLD) by mid-2011. LPLD is characterised by a marked increase in triglycerides which can lead to serious complications such as acute recurring pancreatitis. Given the progressive nature of LPLD, early diagnosis is crucial to patients in order to reduce mortality and morbidity.